Giuseppe Derosa

Giuseppe Derosa's AcademicInfluence.com Rankings

Giuseppe Derosa

Medical

#3428

World Rank

#3896

Historical Rank

Pharmacology

#431

World Rank

#484

Historical Rank

medical Degrees

Download Badge

Medical

Giuseppe Derosa's Degrees

PhD Pharmacology University of Milan
Masters Pharmacy University of Milan
Bachelors Pharmacy University of Milan

Why Is Giuseppe Derosa Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giuseppe Derosa's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sulfonylureas and their use in clinical practice (2015) (321)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. (2020) (256)
α-Glucosidase inhibitors and their use in clinical practice (2012) (251)
Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. (2004) (179)
Anti-obesity drugs: a review about their effects and their safety (2012) (161)
Matrix metalloproteinase-2 and -9 levels in obese patients. (2008) (151)
A role for quercetin in coronavirus disease 2019 (COVID‐19) (2020) (150)
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials (2012) (140)
Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases (2016) (133)
Exenatide versus glibenclamide in patients with diabetes. (2010) (128)
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. (2006) (128)
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. (2004) (127)
Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. (2016) (127)
Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men (2002) (125)
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. (2007) (125)
Influence of losartan and atenolol on memory function in very elderly hypertensive patients (2003) (124)
The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. (2003) (123)
The role of various peroxisome proliferator‐activated receptors and their ligands in clinical practice (2018) (114)
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone (2017) (111)
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. (2010) (109)
Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients (2007) (108)
Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study (2013) (101)
RICE BRAN AND ITS MAIN COMPONENTS: POTENTIAL ROLE IN THE MANAGEMENT OF CORONARY RISK FACTORS (2005) (99)
Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. (2002) (96)
Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. (2004) (93)
Metformin–pioglitazone and metformin–rosiglitazone effects on non‐conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome (2006) (84)
Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study (2021) (83)
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial (2021) (81)
Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α (2006) (79)
Effects of berberine on lipid profile in subjects with low cardiovascular risk (2013) (78)
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. (2003) (77)
Exosomes: Nanoparticulate tools for RNA interference and drug delivery (2017) (76)
Different Effect of Psyllium and Guar Dietary Supplementation on Blood Pressure Control in Hypertensive Overweight Patients: A Six-Month, Randomized Clinical Trial (2007) (74)
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. (2008) (73)
Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. (2002) (72)
Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. (2003) (71)
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. (2004) (71)
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients (2005) (71)
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone (2007) (70)
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. (2012) (70)
Ellagic Acid and Its Role in Chronic Diseases. (2016) (70)
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. (2011) (69)
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. (2005) (68)
Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study (2017) (67)
Dipeptidyl peptidase-4 inhibitors: 3 years of experience. (2012) (66)
Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. (2015) (64)
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. (2006) (64)
Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet (2009) (61)
Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. (2013) (60)
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. (2012) (59)
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome (2007) (59)
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. (2012) (59)
Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin (2007) (59)
Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. (2012) (59)
Piperine and Its Role in Chronic Diseases. (2016) (58)
Comparison of the Effects of Valsartan and Felodipine on Plasma Leptin and Insulin Sensitivity in Hypertensive Obese Patients (2005) (58)
Exenatide plus metformin compared with metformin alone on β‐cell function in patients with Type 2 diabetes (2012) (58)
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. (2010) (57)
What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks (2004) (56)
GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. (2012) (55)
Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. (2007) (54)
A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients (2016) (53)
Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients (2013) (53)
Omega 3 Polyunsaturated Fatty Acids Supplementation and Blood Pressure Levels in Hypertriglyceridemic Patients with Untreated Normal-High Blood Pressure and With or Without Metabolic Syndrome: A Retrospective Study (2010) (53)
Dietary and nutraceutical approach to type 2 diabetes (2014) (53)
Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. (2016) (52)
Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus (2010) (52)
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin (2007) (52)
Naturally occurring anti-cancer agents targeting EZH2. (2017) (51)
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. (2010) (50)
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. (2003) (50)
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. (2004) (49)
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. (2011) (49)
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. (2004) (49)
Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride (2005) (49)
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. (2012) (49)
Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. (2016) (48)
Anemia in patients with Covid-19: pathogenesis and clinical significance (2021) (48)
Effects of 1‐year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes (2012) (46)
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes (2009) (45)
Curcumin: A Natural Pan-HDAC Inhibitor in Cancer. (2018) (45)
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects (2009) (44)
Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. (2016) (44)
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2‐year study evaluation (2014) (44)
Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. (2005) (44)
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. (2013) (43)
Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis (2016) (43)
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients (2006) (43)
A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure (2016) (42)
Optimizing combination treatment in the management of type 2 diabetes (2007) (42)
Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. (2003) (42)
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. (2010) (41)
Effects of Siberian ginseng (Eleutherococcus senticosus maxim.) on elderly quality of life: a randomized clinical trial. (2004) (41)
Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. (2007) (40)
Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. (2010) (40)
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. (2011) (40)
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients (2011) (40)
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis (2012) (40)
A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. (2003) (39)
Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients (2009) (39)
Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. (2004) (39)
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. (2008) (39)
Effects of thiazolidinediones and sulfonylureas in patients with diabetes. (2010) (37)
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial (2006) (37)
Effect of Telmisartan and Ramipril on Atrial Fibrillation Recurrence and Severity in Hypertensive Patients With Metabolic Syndrome and Recurrent Symptomatic Paroxysmal and Persistent Atrial Fibrillation (2012) (37)
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients (2010) (36)
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients (2009) (36)
Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. (2007) (35)
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. (2005) (35)
Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. (2009) (34)
Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. (2013) (34)
Efficacy and safety of two treatment combinations of hypertension in very elderly patients. (2009) (33)
Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. (2015) (33)
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin (2010) (33)
Comparison between orlistat plus l‐carnitine and orlistat alone on inflammation parameters in obese diabetic patients (2011) (32)
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. (2014) (32)
Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes (2017) (31)
Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. (2016) (31)
Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy (2020) (31)
Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. (2008) (31)
Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension (2010) (31)
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. (2013) (31)
Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. (2015) (30)
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. (2010) (30)
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. (2011) (29)
Effects of n‐3 PUFA on insulin resistance after an oral fat load (2011) (29)
Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. (2010) (28)
Antithrombotic Effects of Rosiglitazone‐Metformin versus Glimepiride‐Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome (2005) (28)
Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus (2004) (28)
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients (2010) (28)
Effects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension (2005) (28)
Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. (2016) (27)
Effect of Telmisartan on Paroxysmal Atrial Fibrillation Recurrence in Hypertensive Patients With Normal or Increased Left Atrial Size (2012) (26)
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes (2011) (26)
Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus (2008) (26)
Drug safety evaluation of amlodipine (2011) (26)
The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. (2016) (26)
Berberis aristata/Silybum marianum fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. (2015) (25)
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. (2008) (25)
Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study (2017) (25)
Quercetin Phytosome® as a potential candidate for managing COVID-19 (2021) (24)
Candesartan effect on inflammation in hypertension (2010) (24)
Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. (2010) (24)
A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus (2016) (24)
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study (2012) (24)
Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. (2011) (24)
Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly (2005) (24)
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial (2009) (23)
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function (2012) (23)
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. (2013) (23)
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. (2008) (23)
Curcuminoids Lower Plasma Leptin Concentrations: A Meta‐analysis (2017) (23)
Efficacy and safety of ezetimibe/simvastatin association on non‐diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment (2009) (22)
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. (2013) (22)
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. (2009) (22)
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. (2007) (22)
Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome (2011) (22)
Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of dIabeteS in obese paTIeNts (The RESISTIN trial). (2019) (22)
Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring (2002) (22)
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial (2012) (21)
Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. (2005) (21)
Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome (2006) (21)
Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. (2013) (21)
Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. (2019) (21)
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. (2009) (21)
Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo‐Controlled Trial (2013) (21)
Long-term Effect of Glimepiride and Rosiglitazone on Non-conventional Cardiovascular Risk Factors in Metformin-treated Patients Affected by Metabolic Syndrome: A Randomized, Double-blind Clinical Trial (2005) (20)
Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. (2004) (20)
Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial (2002) (20)
Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. (2018) (20)
Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. (2008) (20)
Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study (2012) (20)
Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. (2009) (20)
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. (2009) (20)
RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. (2011) (19)
Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy (2006) (19)
Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. (2009) (19)
Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients (2010) (19)
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus (2015) (18)
IFN-γ low production capacity in type 1 diabetes mellitus patients at onset of disease (2005) (18)
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. (2007) (18)
A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. (2014) (18)
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin (2013) (18)
Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study (2019) (18)
Auraptene and Its Role in Chronic Diseases. (2016) (18)
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients (2013) (17)
Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). (2009) (17)
Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: A possible role for the coenzyme Q10? (2005) (17)
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. (2008) (17)
Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome (2009) (17)
Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study (2015) (17)
Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study (2011) (17)
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. (2014) (17)
Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin (2009) (17)
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. (2008) (16)
Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. (2015) (16)
Smaller, denser LDL particles are not a risk factor for cardiovascular disease in healthy nonagenarian women of the Cremona Population Study. (1998) (16)
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. (2007) (16)
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients (2010) (16)
Red yeast rice and statin-intolerant patients. (2010) (16)
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients (2014) (16)
Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: a 12-years follow-up of the Brisighella Heart Study historical cohort. (2014) (16)
Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients (2019) (15)
Effects of canrenone in patients with metabolic syndrome (2013) (15)
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β‐cell function: the triple oral therapy (2013) (15)
Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients (2011) (15)
Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension (2011) (15)
Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies (2019) (15)
Olmesartan/Amlodipine Combination Versus Olmesartan or Amlodipine Monotherapies on Blood Pressure and Insulin Resistance in a Sample of Hypertensive Patients (2013) (14)
Relationship Between Serum Uric Acid and Electrocardiographic Alterations in a Large Sample of General Population: Data From the Brisighella Heart Study (2015) (14)
Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice (2015) (14)
Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic Patients with or without Chronic Kidney Disease (2013) (13)
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients (2011) (13)
P-9: Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients (2002) (13)
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus (2015) (13)
Synergistic Effect of Doxazosin and Acarbose in Improving Metabolic Control in Patients with Impaired Glucose Tolerance (2006) (13)
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy (2012) (13)
Retargeting the management of hypercholesterolemia – focus on evolocumab (2016) (13)
Effect of ezetimibe on plasma adipokines: a systematic review and meta‐analysis (2017) (13)
Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. (2017) (12)
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria (2014) (12)
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus (2012) (12)
Pioglitazone is a Valid Alternative to Rosiglitazone (2011) (12)
High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction (2017) (12)
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk (2015) (12)
Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. (2010) (12)
Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. (2014) (12)
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. (2013) (11)
Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine (2010) (11)
Pioglitazone plus glimepiride: a promising alternative in metabolic control (2007) (11)
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies (2013) (11)
Retracted: Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies (2013) (11)
Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension (2007) (11)
Retracted: Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes (2014) (11)
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. (2009) (11)
Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials. (2006) (10)
An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia (2019) (10)
Time to Achieve Blood Pressure Goal with a Combination Versus a Conventional Monotherapy Approach in Hypertensive Patients with Metabolic Syndrome (2010) (10)
Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes (2018) (10)
Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type 2 diabetes and microalbuminuria: An open-label, uncontrolled study (2002) (10)
Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. (2015) (10)
Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy (2007) (10)
Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. (2012) (10)
Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials. (2017) (10)
Effect of Doxazosin on C-Reactive Protein Plasma Levels and on Nitric Oxide in Patients With Hypertension (2006) (9)
IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease. (2005) (9)
Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients (2012) (9)
Probiotic Therapy With VSL#3® in Patients With NAFLD: A Randomized Clinical Trial (2022) (9)
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. (2016) (9)
Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers (2021) (9)
Irbesartan and hydrochlorothiazide association in the treatment of hypertension. (2009) (9)
Prospects for the development of novel anti-hyperlipidemic drugs. (2006) (9)
Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients (2019) (8)
The effects of canrenone on inflammatory markers in patients with metabolic syndrome (2015) (8)
Quercetin Phytosome® as a potential drug for Covid-19. (2020) (8)
Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy (2019) (8)
Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre‐diabetes (2020) (8)
Correction to: Anemia in patients with Covid-19: pathogenesis and clinical significance (2021) (8)
Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies (2016) (8)
Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. (2014) (7)
Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients (2003) (7)
Traditional Markers in Liver Disease (2017) (7)
Hypoglycemia, its implications in clinical practice, and possible ways to prevent it (2014) (7)
Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo‐Controlled Trial (2015) (7)
Erratum: Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension (Journal of the Renin-Angiotensin-Aldosterone System (2007) vol. 8 (139-144)) (2007) (7)
Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications (2021) (7)
Are there mild and serious metabolic syndromes? The need for a graded diagnosis. (2014) (7)
Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients (2018) (7)
Effects of two different dialytic treatments on inflammatory markers in people with end‐stage renal disease with and without type 2 diabetes mellitus (2017) (7)
Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate (2013) (7)
Abscisic Acid Treatment in Patients with Prediabetes (2020) (6)
Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure (2013) (6)
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination (2010) (6)
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus (2015) (6)
Glimepiride-pioglitazone Hydrochloride in the Treatment of Type 2 Diabetes (2009) (6)
Nifedipine and telmisartan for the treatment of hypertension: the TALENT study (2011) (6)
Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes (2015) (6)
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria (2013) (6)
Lipid-lowering nutraceuticals update on scientific evidence (2020) (5)
Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. (2020) (5)
Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention (2020) (5)
RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients (2014) (5)
Retraction Note to: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients (2014) (5)
Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption (2017) (5)
Effects of a nutraceutical combination of monacolin, γ-oryzanol and γ-aminobutyric acid on lipid profile and C-reactive protein in mice (2018) (4)
Effect of oral chronic isoﬂavones supplementation on male rat sexual performances and sexual hormone plasma levels (2004) (4)
Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients (2017) (4)
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients (2018) (4)
Canrenone on cardiovascular mortality in congestive heart failure CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE‐IT study (2019) (4)
Abstract: P783 EFFECT OF MANIDIPINE-ROSUVASTATIN COMBINATION ON FIBRINOLYSIS, INFLAMMATION MARKERS AND INSULIN SENSITIVITY IN HYPERTENSIVE HYPERCHOLESTEROLEMIC PATIENTS (2009) (4)
Overview of Biochemical Markers of Bone Metabolism (2016) (4)
Galectin-3 Plasma Levels Are Associated with Risk Profiles in Pulmonary Arterial Hypertension (2020) (4)
Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy? (2016) (4)
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial (2015) (4)
Glyco‐metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study) (2020) (4)
P-86: Effect of losartan irbesartan and candesartan on platelet aggregability and fibrinolysis in type 2 diabetic hypertensive patients (2002) (4)
Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study (2022) (4)
OR-50: Effect of manidipine and lisinopril on albuminuria and ventricular mass in diabetic hypertensive patients with microalbuminuria (2001) (4)
Efficacy and safety of two dosages of canrenone as add‐on therapy in hypertensive patients taking ace‐inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE‐IT trial (2016) (4)
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV (2021) (3)
Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy (2006) (3)
Berberine induced improvement in hepatic steatosis index in overweight dyslipidaemic patients treated with lipid-lowering nutraceuticals (2013) (3)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease (2019) (3)
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria (2013) (3)
Abstract 4100: Atorvastatin Addition to Losartan or to Atenolol and Recurrence of Paroxysmal Atrial Fibrillation in Hypertension (2008) (3)
Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy (2020) (3)
PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients (2020) (3)
Comparison between diet, orlistat and cerivastatin in hypercholesterolemic, obese patients, with mild hypertension (2001) (3)
A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study (2008) (3)
Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Liver Disease (2016) (3)
P-10: Different effect of valsartan and lisinopril on sildenafil use in hypertensive men with erectile dysfunction (2002) (3)
Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. (2015) (3)
Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors (2010) (2)
COVID-19 pandemic impact on people with diabetes: results from a large representative sample of Italian older adults (2022) (2)
Sitagliptin: results from clinical practice (2013) (2)
Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus (2006) (2)
20 LOSARTAN ALONE OR COMBINED WITH SIMVASTATIN IMPROVED VISCERAL ADIPOSE TISSUE AND INFLAMMATION IN HYPERTENSIVE NORMOCHOLESTEROLEMIC PATIENTS WITH NON-ALCOHOLIC HEPATIC STEATOSIS (2011) (2)
LONG-TERM EFFECTS OF A BERBERINE BASED NUTRACEUTICAL ON BODY WEIGHT AND INSULIN-SENSITIVITY IN NON DIABETIC HYPERLIPIDAEMIC PATIENTS: PP.2.43 (2011) (2)
Effect of valsartan on insulin sensitivity and leptin in hypertensive obese patients (2004) (2)
P-8: Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension (1999) (2)
Management of type 2 diabetes mellitus in chronic kidney disease (2015) (2)
Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimcina), White Mulberry and Chromium Picolinate in Nondiabetic Subects with Dysglycemia: A Randomized Trial (2021) (2)
Effect of perindopril and atenolol on plasma PAI-1 in hypertensive patients with acute ischemic stroke (2002) (2)
Optimizing glycemic control: clinical utility of exenatide prolonged release injection (2012) (2)
EXAMINE: targeting risk and treatment in diabetes (2015) (2)
P124 Effect of losartan irbesartan and candesartan on platelet aggregability and fibrinolysis in type 2 diabetic hypertensive patients (2003) (2)
Clinical and microscopical features of small-intestinal microsporidiosis in patients with AIDS (1995) (2)
Proprotein convertase subtilisin/kexin type 9 inhibitors treatment in dyslipidemic patients: a real world prescription. (2021) (2)
P-6: Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients (1997) (2)
Difference in incidence of cough induced by imidapril and ramipril: Role of prostaglandin synthesis inhibition (2011) (2)
Possible therapies for obesity: focus on the available options for its treatment. (2015) (1)
[27] RISK PERCEPTION AND QUALITY OF LIFE IN CHILDREN WITH FAMILIAL HYPERLIPIDEMIAS AND THEIR PARENTS BEFORE AND AFTER LIFE-STYLE COUNSELING (2009) (1)
Subjective effects of a combined lipid-lowering nutraceutical or ezetimibe on well-being and sexual performance in patients with perceived worsening of erectile function during statin treatment: a randomised clinical trial (2015) (1)
Homocysteine and cardiovascular risk (multiple letters) (2003) (1)
Histological Biomarkers of Nonalcoholic Fatty Liver Disease (2016) (1)
Lipoprotein (a) Particles Characterization by Dynamic Light Scattering (2016) (1)
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women. (2004) (1)
Risk management in the treatment of type 2 diabetes with pioglitazone (2009) (1)
P-454: Effect of manidipine-simvastatin combination on fibrinolysis, adhesion molecules and C-reactive protein in hypertensive hypercholesterolemic patients (2005) (1)
Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles (2015) (1)
Evaluation of the Effects of a Supplement Composed by Quercetin, Rutin, Bromelain and L-Carnosine in Patients with Borderline Uricemia (2020) (1)
The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature (2022) (1)
Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin (2011) (1)
Glibenclamide and cardio-metabolic risk: a systematic review (2014) (1)
P-521: Effect of valsartan on adiponectine, leptin and resistine in hypertensive obese patients (2005) (1)
35 EVALUATION OF METALLOPROTEINASE 2 AND 9 LEVELS AND THEIR INHIBITORS IN COMBINED DYSLIPIDEMIA DURING OMEGA-3 POLYUNSATURATED FATTY ACIDS THERAPY (2008) (1)
EFFECT OF ALISKIREN ADDITION TO AMLODIPINE ON ANKLE EDEMA AND SUBUCUTANEOUS TISSUE PRESSURE IN HYPERTENSIVE PATIENTS: PP.5.183 (2010) (1)
Efficacy of Berberis aristata Compared to Metformin in Improving Glycemic Control and Insulin Resistance in Patients with Type 2 Diabetes Mellitus (2020) (1)
MS2 EFFECTS OF SIBUTRAMINE PLUS L-CARNITINE COMPARED TO SIBUTRAMINE OR PLACEBO ON INFLAMMATORY PARAMETERS (2010) (1)
Abstract 9533: Effect of Combined Ramipril-Canrenone on Atrial Fibrillation Recurrence in Hypertensive Patients With a History of Paroxysmal Atrial Fibrillation (2014) (1)
A curious case of hypoglycaemia (2013) (1)
Ketanserin effects on insulin sensitivity in nonobese, nondiabetic hypertensive patients: an evaluation by the euglycemic-hyperinsulinemic clamp technique. (1995) (1)
Evaluation in Patients with High NORMAL Blood Pressure of a Supplement Containing Arginine, Lactobacillus Plantarum Lp-LDL, Coenzime Q10 and Vitamin B1: A PILOT Study (2020) (1)
Original article Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study (2012) (1)
Effect of Esterol Tens® Compared to Placebo in Hypercholesterolemic Hypertensive Patients after an Oral Fat Load (2020) (1)
Original article Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study (2012) (1)
Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study (2013) (1)
Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients (2021) (1)
We-P11:65 Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin (2006) (1)
Inhaled insulin: weighing the pros and cons. (2015) (1)
29 EFFECT OF PHYSICAL ACTIVITY ON VASCULAR REMODELLING BIOMARKERS IN HYPERTENSIVE OVERWEIGHT PATIENTS (2008) (0)
PO22-698 EFFECT OF TELMISARTAN ON FASTING AND POSTPRANDIAL INFLAMMATION MARKERS IN DIABETIC HYPERTENSIVE PATIENTS (2007) (0)
Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardio-vascular disease: response to Beishuizen et al. (2005) (0)
Female Sexual Dysfunction in Subjects with Type 2 Diabetes Mellitus (2023) (0)
Role of vitamin D in insulin resistance (2018) (0)
6D.07: AMLODIPINE ALONE COMPARED TO AMLODIPINE + ACETYLSALICYLIC ACID ON INFLAMMATION AND ENDOTHELIAL DAMAGE MARKERS IN HYPERTENSIVE PATIENTS (2015) (0)
Pharmacotherapy for Obesity (2014) (0)
Abstract 8236: Effect of Telmisartan on Paroxymal Atrial Fibrillation in Hypertensive Patients with Different Left Atrial Size (2011) (0)
LIPOPROTEIN (A) LEVELS PREDICT PULSE WAVE VELOCITY IN SUBJECTS IN PRIMARY PREVENTION FOR CARDIOVASCULAR DISEASE WITH LARGE APO(A) ISOFORMS: DATA FROM THE BRISIGHELLA HEART STUDY. (2022) (0)
Rosiglitazone Maleate and Glimepiride in Fixed Combination for the Metabolic Control of Type 2 Diabetes (2011) (0)
DIFFERENT EFFECTS OF ALISKIREN/HYDROCHLOROTIAZIDE AND ATENOLOL/HYDROCHLOROTIAZIDE COMBINATIONS ON CENTRAL PRESSURE IN ELDERLY HYPERTENSIVE PATIENTS (2010) (0)
Effects of olmesartan/amlodipine fixed combination compared to single monotherapies on levels of some new emerging biomarkers in cardiovascular risk stratification in hypertensive, type 2 diabetic subjects (2015) (0)
EFFECT OF A COMBINED NUTRACEUTICAL ADDED TO THERAPEUTIC LIFE-STYLE ON BIOMARKERS OF VASCULAR REMODELLING IN OVERWEIGHT AND NORMOWEIGHT DYSLIPIDAEMIC SUBJECTS: A CONTROLLED TRIAL: PP.2.48 (2011) (0)
Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". (2017) (0)
Gender specific haemodinamic and metabolic effects of a sequential training program on hypertensive overweight patients. (2009) (0)
Expression of concern (2018) (0)
EFFECT OF MANIDIPINE AND ATENOLOL ON PLATELET AGGREGABILITY IN ISOLATED SYSTOLIC HYPERTENSION WITH AND WITHOUT TYPE 2 DIABETES MELLITUS: P2.255 (2004) (0)
Retraction: ‘Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies’ by G. Derosa, A. F. G. Cicero, A. Carbone, F. Querci, E. Fogari, A. D'Angelo and P. Maffioli (2016) (0)
Evaluation of single and associated botanicals on glucose tolerance in glucose induced hyperglycemic mice (2022) (0)
LONG-TERM EFFICACY AND SAFETY OF A COMBINED NUTRACEUTICAL ADDED TO THERAPEUTIC LIFE-STYLE IN OVERWEIGHT AND NORMOWEIGHT DYSLIPIDAEMIC SUBJECTS: A CONTROLLED TRIAL: PP.2.47 (2011) (0)
P6583Oral anticoagulants in diabetic and nondiabetic patients with non-valvular atrial fibrillation (2018) (0)
RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients (2013) (0)
Related articles (2013) (0)
Obesity (2008) (0)
Effects Of Pcsk-9 Inhibitors On Lipid Profile: An Italian, Real Life, Multicentric Experience (2019) (0)
27 METABOLIC EFFECT OF A SEQUENTIAL TRAINING PROGRAM ON HYPERTENSIVE OVERWEIGHT PATIENTS WITH AND WITHOUT METABOLIC SYNDROME (2008) (0)
Abstract: P782 EFFECTS OF ATORVASTATIN-FENOFIBRATE COMBINATION COMPARED TO ATORVASTATIN MONOTHERAPY ON LIPID PROFILE IN PATIENTS WITH COMBINED DYSLIPIDEMIA (2009) (0)
Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33]. (2018) (0)
Abstract: P1266 EFFICACY OF SIMVASTATIN AND FENOFIBRATE ASSOCIATION IN HYPERCHOLESTEROLEMIC, TYPE 2 DIABETIC PATIENTS COMPARED TO MONOTHERAPY (2009) (0)
Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases (2016) (0)
Effects of a Non Dairy Cheese Cream Containing Fermented Soybean Extract on Lipid Profile and Lipoproteins in Dyslipidemic Patients (2019) (0)
P2975 Matrix metalloproteinase 2 may be a marker of microangiopathy compared to metalloproteinase 9 in children and adolescents with type 1 diabetes mellitus: a 5-year follow-up study (2003) (0)
Abstract 333: Effect of Valsartan or Ramipril Addition to Amlodipine/Hydrochlorotiazide Combination on Left Ventricular Hypertrophy in Hypertensive Patients With Type 2 Diabetes (2012) (0)
EFFECT OF TELMISARTAN ON PAROXYSMAL ATRIAL FIBRILLATION IN HYPERTENSIVE PATIENTS WITH DIFFERENT LEFT ATRIAL SIZE: 5A.01 (2011) (0)
Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function (2019) (0)
Detection of sieric BAG3 in patients affected by cardiovascular diseases: State of art and perspectives (2021) (0)
Current and Emerging Pharmacotherapies for the Management of Hypertension, Focus on Aliskiren (2012) (0)
Is it time to implement a standardized oral glucose and fat load test to detect high risk patients? Probably not yet…. (2015) (0)
Olea Europaea Effects on Glyco-Metabolic Parameters and on Glycemic Status in Patients with Impaired Fasting Glucose (2022) (0)
Coment on: The Influence of Statin Medications on Prostate-Specific Antigen Levels. Autrhors' reply (2009) (0)
Editorial Management of type 2 diabetes mellitus in chronic kidney disease (2015) (0)
Letter to the editor (2003) (0)
Correction to: Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy (2021) (0)
Therapy, Pharmacoeconomics and Pharmacovigilance (2008) (0)
11.11 Effect of Valsartan-Amlodipine Combination on Cognitive Function In Elderly Hypertensive Patients (2008) (0)
PO9-200 INFLAMMATION MARKERS AND MMPS IN NONDIABETIC AND DIABETIC SUBJECTS DURING OGTT (2007) (0)
Estimating the burden of hyperlipidemia in a hypertensive ambulatory population (2006) (0)
Diabetes: Safety and efficacy of albiglutide—results from two trials (2014) (0)
W22 QUALITY OF LIFE OF CHILDREN WITH FAMILIAL HYPERLIPIDEMIAS AFTER QUANTITATIVE OR QUALITATIVE DIETARY RESTRICTION (2010) (0)
EFFECT OF ALISKIREN ON QT DISPERSION IN DIABETIC AND NON DIABETIC HYPERTENSIVE PATIENTS: PP.27.357 (2011) (0)
PO11-311 MMP-2, MMP-9 AND THEIR INHIBITORS AND OTHER PROTHROMBOTIC RISK FACTORS PLASMA LEVEL IN FCH, MS, FCH+MS AND CONTROL SUBJECTS (2007) (0)
EVALUATION OF BAG 3 LEVELS IN HEALTHY SUBJECTS , HYPERTENSIVE PATIENTS , AND HYPERTENSIVE DIABETIC PATIENTS † Running title : BAG 3 levels in diabetes and hypertension (2017) (0)
Effect of Valsartan on Adiponectine, Leptin and Resistine in Hypertensive Obese Patients: 5.14 (2005) (0)
25 LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME (2008) (0)
Re: The influence of statin medications on prostate-specific antigen levels. (2009) (0)
DDDT_A_223153 3647..3655 (2019) (0)
W01.18 Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes (2004) (0)
Abstract 2759: Effect of Telmisartan and Ramipril on Atrial Fibrillation Episodes Recurrence and Severity in Hypertensive Patients With Metabolic Syndrome and Lone Paroxysmal Atrial Fibrillation (2009) (0)
Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39. (2015) (0)
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial (2023) (0)
Fenofibrate and fluvastatin compared to monotherapy in hypercholesterolemic diabetic patients with coronary heart disease: a 1 year study (2002) (0)
Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach (2014) (0)
Effect of manidipine and atenolol on platelet aggregability in isolated systolic hypertension with and without type 2 diabetes mellitus (2004) (0)
Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus (2006) (0)
Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428. (2015) (0)
[OP.4C.09] COMPARISON BETWEEN CANRENONE OR HYDROCHLOROTHIAZIDE IN ADDITION TO SARTANS IN HYPERTENSIVE DIABETIC PATIENTS (2016) (0)
Antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria (2013) (0)
Comparison of different types of group practices in an in-hospital ambulatory setting. (1977) (0)
Coenzyne Q10 effect on the serum creatinine increase associated to rosuvastatin 20 mg in severe hypercholesterolemic patients (2005) (0)
Retraction Note to: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients (2015) (0)
The Role of Apolipoprotein APO A-IV in Eating Behavior and Diet (2011) (0)
P-288: Sex steroid hormones in middle age hypertensive men (2002) (0)
EFFECT OF AMLODIPINE-ATORVASTATIN COMBINATION ON FIBRINOLYSIS IN HYPERTENSIVE HYPERCHOLESTEROLEMIC INSULIN-RESISTANT PATIENTS: P3.263 (2004) (0)
[PP.22.14] ENALAPRIL/LERCANIDIPINE 20/20 MG COMPARED TO ENALAPRIL/HYDROCHLOROTIAZIDE 20/12.5 MG ON BLOOD PRESSURE VALUES AND METABOLIC PARAMETERS IN HYPERTENSIVE DIABETIC PATIENTS (2017) (0)
[PP.13.10] EFFICACY AND SAFETY OF TWO DIFFERENT DOSAGES OF CANRENONE AS ADD-ON THERAPY IN HYPERTENSIVE PATIENTS TAKING ACE-INHIBITORS OR SARTANS AND DIURETICS AT MAXIMUM DOSAGE: THE ESCAPE TRIAL (2016) (0)
W01.17 Matrix metalloproteinase 2 and 9 evaluation in patients with or without diabetes during acute coronary syndrome and after the acute event (2004) (0)
28 PHYSICAL TRAINING MODULATION OF PROTHROMBOTIC AND MICROINFLAMMATORY PARAMETERS IN HYPERTENSIVE OVERWEIGHT PATIENTS (2008) (0)
Effects of an olmesartan/amlodipine combination compared to olmesartan or amlodipine monotherapies on some insulin resistance parameters in hypertensive patients (2013) (0)
Properties and uses of Olea europaea (2021) (0)
Expression of concern (2018) (0)
PP.21.21: EFFECTS OF OLMESARTAN/AMLODIPINE FIXED COMBINATION ON LEVELS OF SOME EMERGING BIOMARKERS IN CARDIOVASCULAR RISK STRATIFICATION IN HYPERTENSIVE, TYPE 2 DIABETIC SUBJECTS (2015) (0)
Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone (2017) (0)
Tu-P7:255 Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients (2006) (0)
EFFECT OF VALSARTAN OR RAMIPRIL ADDITION TO AMLODIPINE/HYDROCHLOROTIAZIDE COMBINATION ON LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES (2012) (0)
Effects of fosinopril on lipid profile and Lp(a) in normotensive patients with type 2 diabetes and microalbuminuria (2001) (0)
Endothelial In fl ammation Markers in Healthy Subjects and Diabetic Patients (2009) (0)
Tu-P7:254 Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy (2006) (0)
DMSOTT-3950-risk management in the treatment (2009) (0)
Effects of sitagliptin on lipid profile in type 2 diabetic patients after seven years of therapy (2018) (0)
Non conventional cardiovascular risk factors distribution in FCH, MS, FCH+MS and control subjects: towards a full disease characterization. (2006) (0)
PO20-625 EFFICACY OF SOLUBLE FIBER SUPPLEMENTATION IN CVD RISK MANAGEMENT OF PATIENTS AFFECTED BY METABOLIC SYNDROME: A 6-MONTHS, OPEN-LABEL, RCT (2007) (0)
We-P11:93 Combining natural treatments to reach lipid target in metabolic syndrome patients: A randomized clinical trial (2006) (0)
Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease (2020) (0)
Editorial Sitagliptin: results from clinical practice (2013) (0)
Effectsoflongchainω-3fatty acidsonmetalloproteinases andtheirinhibitorsincombined dyslipidemiapatients (2009) (0)
DIFFERENT EFFECTS OF ALISKIREN AND LOSARTAN ON FIBRINOLYSIS AND INSULIN SENSITIVITY IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME: 8B.01 (2010) (0)
Nutraceutical Herbs and Insulin Resistance (2019) (0)
Atorvastatin-amlodipine combination and fibrinolytic balance in hypertensive hypercholesterolemic insulin-resistent patients (2004) (0)
Botanicals and Food Supplement Combination in Patients with Polygenic Hypercholesterolemia: Evaluation at Fasting and after Oral Fat Load Test (2020) (0)
Comparison between perindopril and candesartan in hypertensive patients with type 2 diabetes: evaluation of lipid profile and Lp (a) (2001) (0)
We-P14:482 Efficacy of soluble fiber supplementation in CV disease risk management of patients with metabolic syndrome: A 6-months, randomized clinical trial (2006) (0)
Retraction notice to "Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients" [Pharmacol. Res. 73 (2013) 20-26]. (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giuseppe Derosa?

Giuseppe Derosa is affiliated with the following schools:

University of Milan
University of Pavia
University of Bologna